欲妇荡岳丰满少妇岳A片,国产午夜精品AV一区二区麻豆,斩龙小说,依依小说

Date: 23-March-2019  
Source:  Guangdong Tencent News

TAEST16001 of Xiangxue has been the first TCR-T IND (Investigational New Drug) in China approved by NMPA (National Medical Products Administration).

With independent intellectual property rights, Xiangxue Life Sciences has established a platform to develop cell-based therapies that take advantage of the unique attributes of TCR mediated target recognition. As first product of company, TAEST16001 reaches the international advanced level. Being considered of the highly effective technology for tumor vaccination, TCR-T has shown the potential to improve cure rate and to save lives of patients with malignant tumor.

廣州市香雪制藥股份有限公司子公司廣東香雪精準(zhǔn)醫(yī)療技術(shù)有限公司向國家藥品監(jiān)督管理局提交的TAEST16001注射液新藥臨床注冊申請已獲得國內(nèi)首個(gè)TCR-T臨床試驗(yàn)許可。

香雪精準(zhǔn)已建立TCR-T完整的技術(shù)平臺(tái)及工藝，具有完整的自主知識(shí)產(chǎn)權(quán)，TAEST16001注射液是香雪精準(zhǔn)研發(fā)管線的第一個(gè)產(chǎn)品，達(dá)到了國際先進(jìn)水平。特異性T細(xì)胞受體免疫治療技術(shù)（TCR-T）是目前在腫瘤免疫治療領(lǐng)域具有顯著療效的先進(jìn)技術(shù)，可實(shí)現(xiàn)疾病的個(gè)體化精準(zhǔn)治療，大大提高腫瘤的治愈率，從而有望從根本上治愈惡性腫瘤這一頑疾。